We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: prostate cancer
MedXY News
EnglishTag

prostate cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer
AIAIMRI

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer

By MedXY|Oct 6, 2025

A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessa

Frequent Ejaculation and Prostate Cancer Risk: Insights from a Landmark Harvard Study
Medical Newscancer preventionejaculation frequency

Frequent Ejaculation and Prostate Cancer Risk: Insights from a Landmark Harvard Study

By MedXY|Oct 6, 2025

A large Harvard study shows men ejaculating 21+ times monthly have a significantly reduced overall risk of prostate cancer, especially low-risk forms, across different life stages.

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials
Oncologyoverall survivalprostate cancer

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

By MedXY|Oct 4, 2025

Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management
Clinical Updatesartificial intelligenceclinical decision support

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management

By MedXY|Aug 19, 2025

ArteraAI Prostate, the first FDA-approved AI-driven multimodal software, offers personalized clinical decision support for localized prostate cancer, improving treatment precision and reducing overtreatment risks.

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis
Clinical UpdatesEnzalutamidepembrolizumab

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY|Oct 2, 2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.

Clinical UpdatesEnzalutamidemCRPC

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By MedXY|Oct 1, 2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
Clinical Updatesprostate cancerRadiotherapy

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY|Oct 1, 2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials
Clinical Updatesandrogen deprivation therapyclinical trial

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials

By MedXY|Oct 1, 2025

Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities